Robert Segal

893 total citations
22 papers, 629 citations indexed

About

Robert Segal is a scholar working on Pulmonary and Respiratory Medicine, Endocrine and Autonomic Systems and Surgery. According to data from OpenAlex, Robert Segal has authored 22 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 11 papers in Endocrine and Autonomic Systems and 5 papers in Surgery. Recurrent topics in Robert Segal's work include Neonatal Respiratory Health Research (20 papers), Neuroscience of respiration and sleep (11 papers) and Respiratory Support and Mechanisms (8 papers). Robert Segal is often cited by papers focused on Neonatal Respiratory Health Research (20 papers), Neuroscience of respiration and sleep (11 papers) and Respiratory Support and Mechanisms (8 papers). Robert Segal collaborates with scholars based in United States, Poland and United Kingdom. Robert Segal's co-authors include Graham Bernstein, Jan Mazela, Janusz Gadzinowski, Fernando Moya, Ralph B. D’Agostino, Neil N. Finer, T. Allen Merritt, Joseph M. Massaro, Sunil K. Sinha and Thierry Lacaze‐Masmonteil and has published in prestigious journals such as PEDIATRICS, European Respiratory Journal and American Journal of Roentgenology.

In The Last Decade

Robert Segal

22 papers receiving 602 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Segal United States	13	539	309	157	64	42	22	629
Benita L. Epstein United States	8	341 0.6×	208 0.7×	84 0.5×	84 1.3×	68 1.6×	10	484
M Hallman United States	14	490 0.9×	254 0.8×	145 0.9×	94 1.5×	64 1.5×	24	774
Elena Cubells Spain	12	181 0.3×	79 0.3×	43 0.3×	119 1.9×	46 1.1×	21	332
Elizabeth M. Zola United States	6	392 0.7×	236 0.8×	151 1.0×	59 0.9×	16 0.4×	8	494
Matthew S. Sell United States	9	259 0.5×	115 0.4×	105 0.7×	39 0.6×	22 0.5×	10	372
Guido Stichtenoth Germany	11	308 0.6×	128 0.4×	69 0.4×	58 0.9×	30 0.7×	37	395
Machiko Ikegami United States	6	413 0.8×	162 0.5×	189 1.2×	65 1.0×	26 0.6×	8	443
Mikko Hallman Finland	13	268 0.5×	108 0.3×	68 0.4×	118 1.8×	26 0.6×	15	428
Debora Santoro Italy	11	238 0.4×	68 0.2×	29 0.2×	21 0.3×	53 1.3×	26	311
E.T. Bucovaz United States	11	137 0.3×	27 0.1×	92 0.6×	119 1.9×	92 2.2×	24	398

Countries citing papers authored by Robert Segal

Since Specialization

Citations

This map shows the geographic impact of Robert Segal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Segal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Segal more than expected).

Fields of papers citing papers by Robert Segal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Segal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Segal. The network helps show where Robert Segal may publish in the future.

Co-authorship network of co-authors of Robert Segal

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Segal. A scholar is included among the top collaborators of Robert Segal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Segal. Robert Segal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gelfand, Craig A., et al.. (2020). Inhaled vitamin A is more effective than intramuscular dosing in mitigating hyperoxia-induced lung injury in a neonatal rat model of bronchopulmonary dysplasia. American Journal of Physiology-Lung Cellular and Molecular Physiology. 319(3). L576–L584. 12 indexed citations

Moya, Fernando, Jan Mazela, Paul Shore, et al.. (2019). Prospective observational study of early respiratory management in preterm neonates less than 35 weeks of gestation. BMC Pediatrics. 19(1). 147–147. 19 indexed citations

Christofidou‐Solomidou, Melpo, Ralph A. Pietrofesa, Evguenia Arguiri, Constantinos Koumenis, & Robert Segal. (2017). Radiation Mitigating Properties of Intranasally Administered KL₄Surfactant in a Murine Model of Radiation-Induced Lung Damage. Radiation Research. 188(5). 571–584. 14 indexed citations

Thomas, Neal J., Fernando Moya, Ira M. Cheifetz, et al.. (2012). A pilot, randomized, controlled clinical trial of lucinactant, a peptide-containing synthetic surfactant, in infants with acute hypoxemic respiratory failure. Pediatric Critical Care Medicine. 13(6). 646–653. 20 indexed citations

Moya, Fernando, et al.. (2012). A Pharmacoeconomic Analysis of In-Hospital Costs Resulting from Reintubation in Preterm Infants Treated with Lucinactant, Beractant, or Poractant Alfa. The Journal of Pediatric Pharmacology and Therapeutics. 17(3). 220–227. 7 indexed citations

Finer, Neil N., et al.. (2010). An Open Label, Pilot Study of Aerosurf ^® Combined with nCPAP to Prevent RDS in Preterm Neonates. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 23(5). 303–309. 121 indexed citations

Terry, Michael, T. Allen Merritt, Jan Mazela, et al.. (2010). Pulmonary Distribution of Lucinactant and Poractant Alfa and Their Peridosing Hemodynamic Effects in a Preterm Lamb Model of Respiratory Distress Syndrome. Pediatric Research. 68(3). 193–198. 16 indexed citations

Sáenz, A., Martín Santos, Á. R. López-Sánchez, et al.. (2010). Beneficial effects of synthetic KL₄surfactant in experimental lung transplantation. European Respiratory Journal. 37(4). 925–932. 12 indexed citations

Laughon, Matthew M., Carl Bose, Fernando Moya, et al.. (2008). A Pilot Randomized, Controlled Trial of Later Treatment With a Peptide-Containing, Synthetic Surfactant for the Prevention of Bronchopulmonary Dysplasia. PEDIATRICS. 123(1). 89–96. 37 indexed citations

10.

Moya, Fernando, Sunil K. Sinha, Janusz Gadzinowski, et al.. (2007). One-Year Follow-up of Very Preterm Infants Who Received Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized, Controlled Trials. PEDIATRICS. 119(6). e1361–e1370. 43 indexed citations

11.

Kinniry, Paul, Deepika Jain, Charalambos Solomides, et al.. (2006). KL₄‐surfactant prevents hyperoxic and LPS‐induced lung injury in mice. Pediatric Pulmonology. 41(10). 916–928. 32 indexed citations

12.

Moya, Fernando, et al.. (2005). 406 Infants with Necrotizing Enterocolitis: Pharmacoeconomic Analysis of Lucinactant (Surfaxin) Versus Pooled Animal-Derived Surfactants in Preventing RDS. Pediatric Research. 58(2). 424–424. 1 indexed citations

13.

Gadzinowski, Janusz, et al.. (2005). 134 Long-Term Outcomes of Lucinactant (Surfaxin) Vs. Animal-Derived and Synthetic, Non–Protein-Containing Synthetic Surfactants in Very Preterm Infants. Pediatric Research. 58(2). 377–377. 1 indexed citations

14.

Moya, Fernando, Janusz Gadzinowski, Eduardo Bancalari, et al.. (2005). A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants. PEDIATRICS. 115(4). 1018–1029. 109 indexed citations

15.

Moya, Fernando, et al.. (2005). 140 Preventing Respiratory Distress Syndrome: A Comparative Pharmacoeconomic Analysis of Lucinactant (Surfaxin) Versus Pooled Animal-Derived Surfactants. Pediatric Research. 58(2). 378–378. 1 indexed citations

16.

Sinha, Sunil K., Thierry Lacaze‐Masmonteil, Thomas E. Wiswell, et al.. (2005). A Multicenter, Randomized, Controlled Trial of Lucinactant Versus Poractant Alfa Among Very Premature Infants at High Risk for Respiratory Distress Syndrome. PEDIATRICS. 115(4). 1030–1038. 130 indexed citations

17.

Moya, Fernando, et al.. (2004). 195 Comparison of Incidences of All-Cause Mortality Between The Novel Surfactant, Surfaxin (Lucinactant) and The Animal Derived Surfactants Survanta (Beractant) and Curosurf (Poractant Alfa). Pediatric Research. 56(3). 497–497. 1 indexed citations

18.

Moya, Fernando, et al.. (2004). 194 Superiority of A Novel Surfactant, Surfaxin (Lucinactant), Over Exosurf (Colfosceril Palmitate) in Prevnting Respiratory Distress Syndrome in Very Preterm Infants: A Pivotal, Multinational, Randomized Trial. Pediatric Research. 56(3). 497–497. 2 indexed citations

19.

Segal, Scott, et al.. (1985). [Administration of a water-alcohol extract of the fir tree (Abies alba) as an aerosol in respiratory tract diseases].. PubMed. 89(1). 123–4. 2 indexed citations

20.

Bp, Drayer, Robert Segal, David Gur, et al.. (1980). Xenon- and iodine-enhanced CT of diffuse cerebral circulatory arrest. American Journal of Roentgenology. 135(1). 97–102. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact